Dermagraft® is an FDA-approved, bioengineered human dermal substitute indicated for the healing of diabetic foot ulcers (DFUs).1
Dermagraft helps restore the compromised wound bed and heal DFUs by providing metabolically active fibroblasts seeded on a bioabsorbable scaffold that produce many of the same proteins and growth factors that support the healing response in healthy skin: human collagen, extracellular matrix (ECM) proteins, and cytokines and growth factors.2,3,4
Dermagraft Directions for Use. Organogenesis. 2013.
Roberts C, Mansbridge J. The scientific basis and differentiating features of Dermagraft. Can J Plast Surg. 2002;10(Suppl A):6A-13A.
Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. Adv Skin Wound Care. 2000;13(suppl 2):6-11.
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366:1736-1743.
Wound Types and Intended Use
Dermagraft is indicated for use in the treatment of full-thickness diabetic foot ulcers greater than six weeks duration, which extend through the dermis but without tendon, muscle, joint capsule, or bone exposure.
Dermagraft should be used in conjunction with standard wound care regimens and in patients that have adequate blood supply to the involved foot.
Dermagraft helps to restore the compromised DFU dermal bed to facilitate healing by providing a substrate over which the patient's own epithelial cells can migrate to close the wound. 1
Through extensive research, Dermagraft has been proven to close more DFUs, faster both in clinical and real-world settings.2,3,4
Roberts C, et al. Can J Plast Surg. 2002;10(suppl A):6A-13A.
Marston WA et al. Diabetes Care. 2003;26(6):1701-1705.
Frykberg R et al. Adv Skin Wound Care. 2015;28(1):17-20.
Kirsner RS et al. Poster presented at: the Symposium on Advanced Wound Care; October 17, 2014; Las Vegas, N.